46 results on '"Kaitu'u-Lino, Tu'uhevaha"'
Search Results
2. Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) is reduced with preeclampsia and small for gestational aged fetuses
3. Characterising side population genes in placentas from patients with preeclampsia and/or fetal growth restriction.
4. The Brain Natriuretic Peptide (BNP) system is expressed in the placenta and vasculature in preeclampsia: potential implications for novel therapeutic strategies
5. Upregulation of placental Ski-like proto-oncogene in preterm preeclampsia: potential target for preeclampsia treatment?
6. Sulfasalazine for the treatment of preeclampsia in a nitric oxide synthase antagonist mouse model
7. In vitro investigation into the regulation and function of SPINT1, a biomarker for fetal growth restriction
8. Therapeutic intervention to alleviate long-term cardiovascular risk following preeclampsia
9. A disintegrin and metalloproteinase 12 (ADAM12) is reduced at 36 weeks’ gestation in pregnancies destined to deliver small for gestational age infants
10. Placental growth factor is negatively regulated by epidermal growth factor receptor (EGFR) signaling
11. New generation antiplatelet agents for the prevention of preeclampsia: enhancing antioxidant pathways in first trimester placenta.
12. Elucidating the function of Sialic acid-binding immunoglobulin-like lectin-6 (SIGLEC6) in preeclampsia.
13. Neuronal cell adhesion molecule (NrCAM) is reduced in pregnancies with small for gestational age.
14. Cystatin 6 (CST6) and Legumain in preeclampsia.
15. Purinergic signalling in the human placenta and functional analysis of purinoceptor P2Y6 in placental development.
16. A global approach to advancing prediction of preeclampsia pathogenesis.
17. High glucose availability alters the proteomic profile of small placental extracellular vesicles and their ability to induce endothelial dysfunction.
18. Prasugrel reduces hypertension and vascular constriction in human and animal models of preeclampsia
19. LOX-1 expression is reduced in placenta from cases of preeclampsia and in hypoxic cytotrophoblasts
20. Analysis of mitochondrial regulatory transcripts in publicly available datasets with validation in placentae from pre-term, post-term and fetal growth restriction pregnancies
21. PSG9 – a novel biomarker deranged in preeclampsia
22. Elevated circulating and placental SPINT2 is associated with placental insufficiency
23. Maternal circulating SPINT1 is reduced in small-for-gestational age pregnancies at 26 weeks: Growing up in Singapore towards health outcomes (GUSTO) cohort study
24. Circulating Tissue Factor Pathway Inhibitor (TFPI) is increased preceding preeclampsia diagnosis and in established preeclampsia
25. Novel approaches to combat preeclampsia: from new drugs to innovative delivery
26. Combining metformin and sulfasalazine additively reduces the secretion of antiangiogenic factors from the placenta: Implications for the treatment of preeclampsia
27. Aurora kinase mRNA expression is reduced with increasing gestational age and in severe early onset fetal growth restriction
28. Circulating Delta-like homolog 1 (DLK1) at 36 weeks is correlated with birthweight and is of placental origin
29. Death associated protein kinase 1 (DAPK-1) is increased in preeclampsia
30. Sulfasalazine decreases soluble fms-like tyrosine kinase-1 secretion potentially via inhibition of upstream placental epidermal growth factor receptor signalling
31. The untapped potential of placenta-enriched molecules for diagnostic and therapeutic development
32. Key players of the necroptosis pathway RIPK1 and SIRT2 are altered in placenta from preeclampsia and fetal growth restriction.
33. Steroid sulfatase is increased in the placentas and whole blood of women with early-onset preeclampsia.
34. Nuclear factor of activated T-cells (NFAT) regulates soluble fms-like tyrosine kinase-1 secretion (sFlt-1) from human placenta.
35. ATF3 is a negative regulator of inflammation in human fetal membranes.
36. Treatment of early onset preeclampsia with sildenafil
37. Circulating Endothelial Transcription Factor GATA2 is decreased in Preeclampsia and may contribute to Maternal Endothelial Dysfunction
38. Mitochondrial biogenesis molecules AMPK, SIRT1 and PGC1α and their relationship to sFlt1 release in preeclampsia
39. New generation antiplatelet therapies to prevent preeclampsia
40. EGF decreases sFlt1 secretion and endothelial dysfunction: A potential therapeutic for preeclampsia
41. Activating transcription factor 3 – A key molecule in the pathogenesis of preeclampsia
42. Proton Pump Inhibitors quench the pathophysiological characteristics of preeclampsia in both human and mouse models and represent an exciting novel candidate therapeutic
43. Proton Pump inhibitors significantly quench pathophysiological characteristics of preeclampsia in primary placental and endothelial models: A novel candidate therapeutic
44. HO-1 expression is not reduced in preeclamptic placenta, and does not regulate sFlt-1 or soluble endoglin secretion in either primary trophoblast or endothelial cells
45. Combination methotrexate and gefitinib (EGFR inhibitor) as a novel therapeutic to medically treat ectopic pregnancies: preclinical studies and human trials
46. Generation and testing of an ELISA that detects the newly discovered primate and placental specific sFlt variant (sFlt1-e15a)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.